Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation
A clinical trial update describing a psychometric evaluation in patients with brain damage during neuroinflammation, with enrollment by invi…
-
FDA approval · 2024-10-15FDA Approved: GABAPENTIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for gabapentin filed by Aurobindo Pharma Limited. This action approves a generic formulation of …
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Center, Non-randomized, Phase I Clinical Trial [Phase 1]
A Phase 1 clinical trial assessing the safety and potential utility of human umbilical cord mesenchymal stem cell secretome for drug-resista…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Cognitive Function and Glymphatic System in Children with Epilepsy [NA]
A completed clinical trial sponsored by Ege University evaluated cognitive function and the glymphatic system in children with epilepsy.
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data
This clinical trial update indicates that the study evaluating the Mjn-SERAS Solution for epilepsy-related quality of life and safety in tre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-10-09FDA Approved: LAMOTRIGINE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for lamotrigine from Ascend Laboratories, granting approval for a generic lamotrigine product.
-
FDA approval · 2024-10-09FDA Approved: LEVETIRACETAM — Supplemental Application (Apotex Corp.)
The FDA approved Apotex Corp.'s supplemental application to market a generic version of levetiracetam.
-
FDA approval · 2024-10-09FDA Approved: LACOSAMIDE — Original Application (Somerset Therapeutics, LLC)
FDA approved the original application for lacosamide by Somerset Therapeutics, LLC, approving a generic version of the anticonvulsant.
-
CLINICAL_TRIALS research · 2024-10-08Clinical Trial Update: Neural Mechanisms for Stopping Ongoing Speech Production [NA]
A UCSF clinical trial investigating neural mechanisms to stop ongoing speech production in individuals with epilepsy; enrollment is by invit…
-
FDA approval · 2024-10-02FDA Approved: PHENYTOIN SODIUM — Supplemental Application (Acella Pharmaceuticals, LLC)
FDA approved a supplemental application for phenytoin sodium from Acella Pharmaceuticals, LLC, approving a supplemental generic product unde…
-
FDA approval · 2024-10-01FDA Approved: LAMOTRIGINE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved a generic lamotrigine product from Alembic Pharmaceuticals Limited under an Original Application (ANDA211821).
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients with Acupuncture Treatment [NA]
This clinical trial update describes clinical and electrographic changes observed in epilepsy patients implanted with a Responsive Neurostim…
-
FDA approval · 2024-09-27FDA Approved: PHENYTOIN — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for phenytoin (PHENYTOIN) by Rising Pharma Holdings, Inc. under an ANDA.
-
FDA approval · 2024-09-24FDA Approved: FELBAMATE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for felbamate from Amneal Pharmaceuticals of New York LLC, expanding the existing approval.
-
FDA approval · 2024-09-24FDA Approved: CLOBAZAM — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for CLOBAZAM (clobazam) from Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Comparison Study of Electrocardiogram Indexes in Patients With Epilepsy, Patients With First Seizure and Normal Population
Completed clinical trial comparing electrocardiogram indices among patients with epilepsy, patients with a first seizure, and a normal popul…
-
CLINICAL_TRIALS research · 2024-09-23Clinical Trial Update: Hybrid Micro-macro Electrodes in Patients with Epilepsy [NA]
This clinical trial is recruiting to evaluate hybrid micro-macro electrodes in patients with epilepsy.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions [Phase 1]
Phase 1 study assessing how cenobamate influences the pharmacokinetics of CYP450 probe drugs to predict potential drug-drug interactions; st…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Thalamic Ventral Intermediate Electrical Stimulation for Refractory Familial Cortical Myoclonus with Epilepsy [NA]
Clinical trial update for thalamic ventral intermediate electrical stimulation in refractory familial cortical myoclonus with epilepsy, curr…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking [NA]
Empatica, Inc. is conducting a recruiting trial to forecast seizures using intelligent wearable technology for health tracking. The study ta…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: iMRI Prone Positioning Frame Design Feasibility Study [NA]
A feasibility study evaluating an iMRI prone positioning frame design, sponsored by the University of Kansas Medical Center; the trial is no…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: The Mosaic Brain: a New Diagnostic Approach in Focal Epilepsies
This clinical trial update describes a new diagnostic approach for focal epilepsies in children and is currently not yet recruiting.
-
FDA approval · 2024-09-16FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for LEVETIRACETAM submitted by Amneal Pharmaceuticals LLC. The action confirms approval of the refer…
-
FDA approval · 2024-09-16FDA Approved: CLOBAZAM — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for CLOBAZAM (clobazam) from Amneal Pharmaceuticals NY LLC under the ANDA pathway.
-
FDA label_change · 2024-09-12FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for Sabril (vigabatrin) by Lundbeck Pharmaceuticals LLC, resulting in a label change to reflect …